Table 3 Number of additional injections (from month 3 to 6) in 3-month nonresponder patients based on the response at 6 months
6-month induction vs 3-month induction | Additional injections | Additional injections in responder patients | Additional injections in nonresponder patients |
|---|---|---|---|
Aflibercept (Eylea®) | 289.57 | 109.57 | 180 |
Ranibizumab (Lucentis®) | 208.98 | 61.98 | 219 |
Bevacizumab (Avastin®) | 393.56 | 39.56 | 354 |